Bita Sahaf

Cancer Prevention Institute of California — United States

Medicine · Health Sciences

37h-index6.9kcitations216works7.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(120), Hematopoietic Stem Cell Transplantation(28), Immune Cell Function and Interaction(28), Chronic Lymphocytic Leukemia Research(23), T-cell and B-cell Immunology(22)

Publications216 total

Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome

Blood Cancer Discovery·2025Open Access

Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine

Blood·2025

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Blood·2025

Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results

Blood·2025Open Access

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Blood·2025Open Access

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Blood·2025

Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)

Blood·2025Open Access

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

Blood·2025Open Access

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Blood·2025Open Access

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Blood·2025Open Access

BIOM-107. EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING

Neuro-Oncology·2025Open Access

269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma

Regular and Young Investigator Award Abstracts·2025Open Access

CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA

Neuro-Oncology·2025Open Access

EPCO-45. SINGLE-CELL LANDSCAPE OF B7H3-CAR T THERAPY IN GLIOMA: MECHANISMS OF RESISTANCE AND SIGNATURES OF LONG-TERM RESPONSE

Neuro-Oncology·2025

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias

2025Open Access

Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

Cytotherapy·2025Open Access

Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity Following Ciltacabtagene Autoleucel in Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia·2025

POSTER: CT-1235 Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma

Clinical Lymphoma Myeloma & Leukemia·2025

CT-1235: Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma

Clinical Lymphoma Myeloma & Leukemia·2025

427 | MONITORING CIRUCLATING TUMOR DNA IMPROVES EARLY RELAPSE DETECTION AFTER STANDARD OF CARE 2L+ AXI‐CEL IN LBCL: A PROSPECTIVE STUDY

Hematological Oncology·2025Open Access

page 1 of 11Next →

Frequent Co-authors

David B. Miklos(28), Lori Muffly(13), Matthew J. Frank(12), Sally Arai(12), Everett Meyer(12), Crystal L. Mackall(11), Jay Y. Spiegel(11), Robert S. Negrin(11), Steven A. Feldman(10), Robert Lowsky(10), Andrew R. Rezvani(10), Crystal L. Mackall(10), Liora M. Schultz(9), Kara L. Davis(9), Surbhi Sidana(9), Sneha Ramakrishna(8), Sharon Mavroukakis(8), Zachary Ehlinger(8), Leonard A. Herzenberg(8), Leonore A. Herzenberg(8)